Synlogic develops synthetic biotic medicines that utilize engineered living therapeutics to perform specific metabolic functions, targeting diseases such as phenylketonuria (PKU). By addressing the underlying metabolic deficiencies, these biotherapeutics aim to transform treatment approaches and improve patient outcomes.
Funding
$21M raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many metabolic diseases, such as phenylketonuria (PKU), result from underlying metabolic deficiencies that are not adequately addressed by existing treatments. Current therapies often fail to target the root cause of the disease, leading to suboptimal patient outcomes.
Solution
Synlogic is developing Synthetic Biotics, a novel class of biotherapeutics, engineered to perform specific metabolic functions within the body. These therapeutics are designed to address the underlying drivers of disease, offering the potential to transform treatment paradigms. By applying synthetic biology, Synlogic aims to create living therapeutics programmed to treat diseases in new ways, ultimately improving patient health.
Target Audience
The primary target audience includes patients with metabolic disorders like PKU and the healthcare professionals who treat them.
Features
- Engineered living therapeutics designed to perform specific metabolic functions.
- Designed to address the underlying drivers of metabolic diseases.
- Potential to transform treatment paradigms for various diseases.